NCT00513669 - Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Falciparum Malaria

Interventions

BIOLOGICAL

PEV 301& 302 in virosomes

PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90

BIOLOGICAL

Inflexal V (active comparator)

Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90

Trial Locations (1)

Bagamoyo Research and Training Unit, Bagamoyo